Supplementary Figure S1 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S1. Tuvusertib in vivo activity in ATM- and ARID1A-mutated xenograft models in mice
Supplementary Figure S1 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors | Synapse